Show simple item record

dc.contributor.authorHolloway, Dustin Ten_US
dc.contributor.authorKon, Marken_US
dc.contributor.authorDeLisi, Charlesen_US
dc.date.accessioned2012-01-11T17:18:24Z
dc.date.available2012-01-11T17:18:24Z
dc.date.copyright2008
dc.date.issued2008-6-18
dc.identifier.citationHolloway, Dustin T, Mark Kon, Charles DeLisi. "In silico regulatory analysis for exploring human disease progression" Biology Direct 3:24. (2008)
dc.identifier.issn1745-6150
dc.identifier.urihttps://hdl.handle.net/2144/3147
dc.description.abstractBACKGROUND. An important goal in bioinformatics is to unravel the network of transcription factors (TFs) and their targets. This is important in the human genome, where many TFs are involved in disease progression. Here, classification methods are applied to identify new targets for 152 transcriptional regulators using publicly-available targets as training examples. Three types of sequence information are used: composition, conservation, and overrepresentation. RESULTS. Starting with 8817 TF-target interactions we predict an additional 9333 targets for 152 TFs. Randomized classifiers make few predictions (~2/18660) indicating that our predictions for many TFs are significantly enriched for true targets. An enrichment score is calculated and used to filter new predictions. Two case-studies for the TFs OCT4 and WT1 illustrate the usefulness of our predictions: • Many predicted OCT4 targets fall into the Wnt-pathway. This is consistent with known biology as OCT4 is developmentally related and Wnt pathway plays a role in early development. • Beginning with 15 known targets, 354 predictions are made for WT1. WT1 has a role in formation of Wilms' tumor. Chromosomal regions previously implicated in Wilms' tumor by cytological evidence are statistically enriched in predicted WT1 targets. These findings may shed light on Wilms' tumor progression, suggesting that the tumor progresses either by loss of WT1 or by loss of regions harbouring its targets. • Targets of WT1 are statistically enriched for cancer related functions including metastasis and apoptosis. Among new targets are BAX and PDE4B, which may help mediate the established anti-apoptotic effects of WT1. • Of the thirteen TFs found which co-regulate genes with WT1 (p ≤ 0.02), 8 have been previously implicated in cancer. The regulatory-network for WT1 targets in genomic regions relevant to Wilms' tumor is provided. CONCLUSION. We have assembled a set of features for the targets of human TFs and used them to develop classifiers for the determination of new regulatory targets. Many predicted targets are consistent with the known biology of their regulators, and new targets for the Wilms' tumor regulator, WT1, are proposed. We speculate that Wilms' tumor development is mediated by chromosomal rearrangements in the location of WT1 targets. REVIEWERS. This article was reviewed by Trey Ideker, Vladimir A. Kuznetsov(nominated by Frank Eisenhaber), and Tzachi Pilpel.en_US
dc.description.sponsorshipNational Institutes of Health (A08 POGM66401A)en_US
dc.language.isoen
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2008 Holloway et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.titleIn Silico Regulatory Analysis for Exploring Human Disease Progressionen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/1745-6150-3-24
dc.identifier.pmid18564415
dc.identifier.pmcid2464594


This item appears in the following Collection(s)

Show simple item record

Copyright 2008 Holloway et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2008 Holloway et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.